XY-17 [(3S)-1-fluoro-3-hydroxy-4-butyl-1-phosphonate (FHBP)] is a fluorinated phosphonate analog of lysophosphatidic acid (LPA). XY-17 is not hydrolyzed by lipid phosphate phosphatase (LPP) and acts as an agonist of the LPA3 receptor.
XY-17 (LPA3 Agonist)
Agonist, Lysophosphatidic Acid
|Molecular Weight (g/mol)||
-20 °C or below
1) Xu, Y., M. Tanaka, et al. (2004). “Alkyl lysophosphatidic acid and fluoromethylene phosphonate analogs as metabolically-stabilized agonists for LPA receptors.” Bioorg Med Chem Lett 14(21): 5323-8.
2) Zhao, Y., P. V. Usatyuk, et al. (2005). “Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells.” Biochem. J. 385(2): 493-502.
3) Prestwich, G., Y. Xu, et al. (2005). “New metabolically stabilized analogues of lysophosphatidic acid: agonists, antagonists and enzyme inhibitors.” Biochem Soc Trans 33: 1357–1361.
4) W.N. Ayre, T. Scott, et al. (2016) “Fluorophosphonate-functionalised titanium via a pre-adsorbed alkane phosphonic acid: a novel dual action surface finish for bone regenerative applications.” J Mater Sci Mater Med. Feb;27(2):36. doi: 10.1007/s10856-015-5644-7